ADVM - Adverum Biotechnologies, Inc. Common Stock
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections.
Recently reported position changes by institutional investors
Recent trades by U.S. Senators
No data for this ticker
Recent trades by U.S. Representatives
No data for this ticker
Quarterly net insider trading by a company's directors and management
Flights by private jets registered to ADVM
No data for this ticker
Federal grants, loans, and purchases. Click on a date for more info.
No data for this ticker